Henrik Nordin

A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry

Bente Glintborg, Inge Juul Sørensen, Anne Gitte Loft et al. · Annals of the Rheumatic Diseases · 2017 · 249 citations

Medicine, Clinical Sciences, Internal Medicine +17

Clinical Response, Drug Survival, and Predictors Thereof Among 548 Patients With Psoriatic Arthritis Who Switched Tumor Necrosis Factor α Inhibitor Therapy: Results from the Danish Nationwide DANBIO Registry

Bente Glintborg, Mikkel Østergaard, Niels Steen Krogh et al. · Arthritis & Rheumatism · 2013 · 203 citations

Medicine, Immunology, Pharmacotherapy +11

Incidences of overall and site specific cancers in TNFα inhibitor treated patients with rheumatoid arthritis and other arthritides – a follow-up study from the DANBIO Registry

Lene Dreyer, Lene Mellemkjær, Anne Rødgaard Andersen et al. · Annals of the Rheumatic Diseases · 2012 · 181 citations · Full text

Medicine, Oncology, Pharmacology +12

To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry

Bente Glintborg, Anne Gitte Loft, Emina Omerovic et al. · Annals of the Rheumatic Diseases · 2018 · 155 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +14

Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry

Bente Glintborg, Mikkel Østergaard, Niels Steen Krogh et al. · Annals of the Rheumatic Diseases · 2012 · 149 citations

Medicine, Clinical Sciences, Pharmacotherapy +10